{
    "eid": "2-s2.0-84919796449",
    "title": "An analysis of legal warnings after drug approval in Thailand",
    "cover-date": "2015-02-01",
    "subject-areas": [
        {
            "$": "Toxicology",
            "@code": "3005"
        }
    ],
    "keywords": [
        "Adverse drug reactions",
        "Drug risk management",
        "Drug safety",
        "Legal warnings",
        "Pharmacovigilance"
    ],
    "authors": [
        "Pakawadee Sriphiromya"
    ],
    "citedby-count": 1,
    "ref-count": 25,
    "ref-list": [
        "Coverage of FDA medication boxed warnings in commonly used drug information resources",
        "Risk management policy and black-box warnings: A qualitative analysis of US FDA proceedings",
        "The teratogenic risk of trimethoprim-sulfonamides: A population based case-control study",
        "How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications",
        "Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999",
        "Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis",
        "Estrogen replacement in menopausal women: Recent and current prospective studies, the WHI and the KEEPS",
        "Selective COX-2 inhibitors and risk of thromboembolic events - Regulatory aspects",
        "A descriptive study of additional risk minimization measures included in risk management plans reviewed by the United Kingdom regulatory authority",
        "Drug allergy",
        "Nimesulide and adverse drug reactions: Time for a database",
        "Timing of new black box warnings and withdrawals for prescription medications",
        "Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin",
        "Risk management from an Asian/Pacific Rim regulatory perspective",
        "\"Black box\" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk",
        "Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study",
        "Population-based case control study of the safety of sulfasalazine use during pregnancy",
        "Different black box warning labeling for same-class drugs",
        "Allergic adverse reactions to sulfonamides",
        "FDA drug prescribing warnings: Is the black box half empty or half full?",
        "Black box warning contraindicated comedications: Concordance among three major drug interaction screening programs",
        "What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling",
        "Messages about black-box warnings: A comparative analysis of reports from the fda and lay media in the US",
        "Black Box Warnings-Implications in Practice"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "affilname": "Thailand Ministry of Public Health",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}